APO 131 (Carbidopa and levodopa extended release 25 mg / 100 mg)

Pill imprint APO 131 has been identified as Carbidopa and levodopa extended release 25 mg / 100 mg.

Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 100 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for APO 131

Carbidopa and levodopa extended release 25 mg / 100 mg APO 131
Carbidopa and levodopa extended release 25 mg / 100 mg APO 131
Carbidopa and levodopa extended release
Imprint:
APO 131
Strength:
25 mg / 100 mg
Color:
Red
Shape:
Round
Availability:
Prescription only
Drug Class:
Dopaminergic antiparkinsonism agents
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Apotex Corp.
National Drug Code (NDC):
60505-0131
Inactive Ingredients:
hypromelloses
magnesium stearate
ferric oxide red
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
00904-5749 Major Pharmaceuticals

Note: Inactive ingredients may vary.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web1)